Champions Oncology Inc (CSBR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.22-1.14%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CSBR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -81.1% |
| Our one-year growth estimate | diamond | 11.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 92.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers
CSBR — earnings in line
Dated 2026-07-27
in this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Why it matters: Positive adjusted EBITDA means the company is getting closer to making money. This is important for growth.
Supportive ifAdjusted EBITDA is positive for the fiscal year.
Worry ifAdjusted EBITDA is still negative for the fiscal year.
Why it matters: More spending on R&D shows a focus on new data and radiopharmaceuticals. This matches management's plans.
Supportive ifR&D spending exceeds $2.5 million in Q3.
Worry ifR&D spending is below $2.5 million in Q3.
Why it matters: Revenue growth shows the company can grow and meet its goals. It means management's plan is working.
Supportive ifQ4 revenue exceeds $16.56M, showing strong growth momentum.
Worry ifQ4 revenue falls below $16.56M, indicating a slowdown in growth.
Why it matters: New data offerings can help the company compete better and earn more money. This is key for growth.
Supportive ifNews about new data offerings or partnerships is coming.
Worry ifNo new data offerings or partnerships announced in the next quarter.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$150 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $501 loss on $10,000 · 5.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,072 loss on $10,000 · 40.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Exceeding 4% growth shows the company is building on its recent revenue gains. This supports management's goal of driving continued revenue growth.
Supportive ifQ3 revenue growth exceeds 4% year over year.
Worry ifQ3 revenue growth is below 4% year over year.
Why it matters: If healthcare sector growth picks up, it may help Champions Oncology's performance. The sector is currently in a maturing phase.
Supportive ifHealthcare sector revenue growth speeds up to 10% or more.
Worry ifHealthcare sector revenue growth slows down below 10%.
Why it matters: Steady revenue growth shows that management wants to grow the business.
Supportive ifRevenue growth reported above 30% year over year in the next earnings report.
Worry ifRevenue growth falls below 20% year over year.
Why it matters: The earnings report will show if Champions Oncology is getting better financially. Investors want to see signs of recovery from losses.
Watch forEarnings report shows revenue growth above 10% year over year.
Also watch forEarnings report shows revenue decline or losses continue.
Why it matters: Positive adjusted EBITDA shows Champions is managing costs well while investing in growth. It is key for long-term viability.
Supportive ifAdjusted EBITDA for Q3 is positive. This continues the trend from earlier quarters.
Worry ifAdjusted EBITDA for Q3 is negative. This shows possible problems with cost management.